OKYO Pharma Ltd ADR - Asset Resilience Ratio

Latest as of June 2026: 28.60%

OKYO Pharma Ltd ADR (OKYO) has an Asset Resilience Ratio of 28.60% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See OKYO Pharma Ltd ADR (OKYO) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

$6.00 Million

Cash + Short-term Investments

Total Assets

$20.98 Million

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2009–2026)

This chart shows how OKYO Pharma Ltd ADR's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see OKYO Pharma Ltd ADR total assets.

Liquid Assets Composition Over Time

This chart breaks down OKYO Pharma Ltd ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read total liabilities of OKYO Pharma Ltd ADR for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$6.00 Million	28.6%
Total Liquid Assets	$6.00 Million	28.60%

Asset Resilience Insights

Very High Liquidity: OKYO Pharma Ltd ADR maintains exceptional liquid asset reserves at 28.60% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

OKYO Pharma Ltd ADR Industry Peers by Asset Resilience Ratio

Compare OKYO Pharma Ltd ADR's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
ALK-Abelló A/S CO:ALK-B	Biotechnology	0.98%
Mirum Pharmaceuticals Inc NASDAQ:MIRM	Biotechnology	6.89%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
BB Biotech AG SW:BION	Biotechnology	92.97%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Wuhan Keqian Biology Co Ltd SHG:688526	Biotechnology	19.42%
Beijing Konruns Pharmaceutical Co Ltd SHG:603590	Biotechnology	10.55%

Annual Asset Resilience Ratio for OKYO Pharma Ltd ADR (2009–2026)

The table below shows the annual Asset Resilience Ratio data for OKYO Pharma Ltd ADR.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2026-03-31	28.60%	$6.00 Million	$20.98 Million	--
2025-03-31	0.00%	$0.00	$3.68 Million	--
2017-03-31	60.74%	$16.86 Million	$27.76 Million	+9.96pp
2010-03-31	50.77%	$27.49 Million	$54.13 Million	-15.22pp
2009-03-31	65.99%	$25.25 Million	$38.27 Million	--

pp = percentage points

About OKYO Pharma Ltd ADR

NASDAQ:OKYO USA Biotechnology

Market Cap

$59.80 Million

Market Cap Rank

#21320 Global

#4797 in USA

Share Price

$1.59

Change (1 day)

-1.85%

52-Week Range

$1.34 - $3.27

All Time High

$3.74